NOBILIS THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nobilistx.com
Xenon Inhalation for Treatment of Panic Disorder
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04432155
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04097080
- Locations
- 🇷🇺
Institute of Addictology, Moscow, Russian Federation
🇷🇺MONIKI, Moscow, Russian Federation
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder
Phase 2
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Combination Product: NBTX-001 Xenon InhalerCombination Product: Placebo
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03635827
© Copyright 2025. All Rights Reserved by MedPath